|
G |
A2m |
alpha-2-macroglobulin |
increases expression |
EXP |
Pilocarpine results in increased expression of A2M mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects expression increases expression |
EXP |
Pilocarpine affects the expression of ABCB1A mRNA Pilocarpine results in increased expression of ABCB1A mRNA; Pilocarpine results in increased expression of ABCB1A protein |
CTD |
PMID:14706787 PMID:17437408 PMID:19055492 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects expression increases expression |
EXP |
Pilocarpine affects the expression of ABCB1B mRNA Pilocarpine results in increased expression of ABCB1B mRNA; Pilocarpine results in increased expression of ABCB1B protein |
CTD |
PMID:14706787 PMID:19055492 PMID:19570321 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects expression |
EXP |
Pilocarpine affects the expression of ABCC1 mRNA |
CTD |
PMID:19055492 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of ABCC2 protein |
CTD |
PMID:16504477 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
affects expression |
EXP |
Pilocarpine affects the expression of ABCC5 mRNA |
CTD |
PMID:19055492 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of ACE mRNA]; [Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of ACE protein] |
CTD |
PMID:32494933 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ache |
acetylcholinesterase |
decreases activity multiple interactions increases expression decreases expression |
EXP ISO |
Pilocarpine results in decreased activity of ACHE protein garcinielliptone FC inhibits the reaction [Pilocarpine results in decreased activity of ACHE protein] 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Pilocarpine results in decreased expression of ACHE protein]; [Thioctic Acid co-treated with Pilocarpine] results in increased activity of ACHE protein; Thioctic Acid inhibits the reaction [Pilocarpine results in decreased expression of ACHE protein] Pilocarpine results in increased expression of ACHE mRNA alternative form; Pilocarpine results in increased expression of ACHE protein alternative form |
CTD |
PMID:16481111 PMID:18242586 PMID:18333967 PMID:19669875 PMID:19932735 PMID:19941057 PMID:20730314 PMID:24911645 More...
|
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Actb |
actin, beta |
multiple interactions |
ISO |
Pilocarpine promotes the reaction [EIF2S1 protein modified form results in decreased expression of ACTB protein] |
CTD |
PMID:16492139 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
EXP |
[2-chloro-N(6)cyclopentyladenosine binds to and results in increased activity of ADORA1 protein] which results in decreased susceptibility to Pilocarpine |
CTD |
PMID:11311893 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adora2a |
adenosine A2a receptor |
affects response to substance |
ISO |
ADORA2A protein affects the susceptibility to Pilocarpine |
CTD |
PMID:19488739 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
increases response to substance |
ISO |
ADRA1B protein results in increased susceptibility to Pilocarpine |
CTD |
PMID:19125850 |
|
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Agrn |
agrin |
increases expression |
EXP |
Pilocarpine results in increased expression of AGRN protein |
CTD |
PMID:17971868 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of AGTR1A protein] |
CTD |
PMID:32494933 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
[Dexamethasone co-treated with Lithium Chloride co-treated with Pilocarpine] affects the expression of AGTR2 mRNA |
CTD |
PMID:32494933 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of AIF1 protein |
CTD |
PMID:18226170 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
increases response to substance |
ISO |
AKAP5 protein mutant form results in increased susceptibility to Pilocarpine |
CTD |
PMID:18711127 |
|
NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
EXP |
Pilocarpine results in decreased phosphorylation of AKT1 protein 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Pilocarpine results in decreased phosphorylation of AKT1 protein]; [Lithium Chloride co-treated with Pilocarpine] results in increased phosphorylation of AKT1 protein; iodopravadoline inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Pilocarpine results in decreased phosphorylation of AKT1 protein]] |
CTD |
PMID:19429016 PMID:30542433 PMID:31018114 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases expression decreases activity multiple interactions |
EXP ISO |
Pilocarpine results in decreased expression of ALAD protein Pilocarpine results in decreased activity of ALAD protein carvacryl acetate inhibits the reaction [Pilocarpine results in decreased activity of ALAD protein] Thioctic Acid inhibits the reaction [Pilocarpine results in decreased expression of ALAD protein]; Ubiquinone inhibits the reaction [Pilocarpine results in decreased expression of ALAD protein] |
CTD |
PMID:19798568 PMID:20026167 PMID:20584200 PMID:25490531 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Ank3 |
ankyrin 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of ANK3 mRNA; Pilocarpine results in increased expression of ANK3 protein |
CTD |
PMID:19306853 |
|
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression affects localization decreases expression |
EXP |
Pilocarpine results in increased expression of APEX1 mRNA Pilocarpine affects the localization of APEX1 mRNA Pilocarpine results in decreased expression of APEX1 protein |
CTD |
PMID:17971868 PMID:20206232 PMID:20446108 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Aplp1 |
amyloid beta precursor like protein 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of APLP1 mRNA |
CTD |
PMID:19448684 |
|
NCBI chr 1:85,696,880...85,707,215
Ensembl chr 1:85,696,882...85,707,155
|
|
G |
Aqp4 |
aquaporin 4 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of AQP4 protein |
CTD |
PMID:20886625 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions affects localization |
ISO |
Atropine inhibits the reaction [Pilocarpine affects the localization of AQP5 protein] |
CTD |
PMID:26208470 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of ASIC1 mRNA |
CTD |
PMID:11162239 |
|
NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of ASIC2 mRNA alternative form |
CTD |
PMID:11162239 |
|
NCBI chr10:65,870,592...66,940,577
Ensembl chr10:65,870,594...66,940,424
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases expression |
EXP |
[Lithium co-treated with Pilocarpine] results in decreased expression of ATF2 protein Pilocarpine results in increased expression of ATF2 mRNA |
CTD |
PMID:17971868 PMID:19430551 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of ATP2A2 protein |
CTD |
PMID:15288437 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atrx |
ATRX, chromatin remodeler |
increases expression |
EXP |
Pilocarpine results in increased expression of ATRX mRNA |
CTD |
PMID:17971868 |
|
NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of BAX mRNA Pilocarpine results in increased expression of BAX mRNA; Pilocarpine results in increased expression of BAX protein |
CTD |
PMID:14754538 PMID:17971868 PMID:19429016 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
[Chlorpyrifos co-treated with Pilocarpine] results in decreased activity of BCHE protein |
CTD |
PMID:22874420 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl10 |
BCL10, immune signaling adaptor |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of BCL10 mRNA Pilocarpine results in increased expression of BCL10 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 2:234,840,880...234,850,520
Ensembl chr 2:234,840,858...234,850,523
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
EXP |
Pilocarpine results in decreased expression of BCL2 protein |
CTD |
PMID:19429016 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression |
EXP |
Pilocarpine results in increased expression of BCL2A1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
decreases response to substance |
ISO |
BDKRB1 protein mutant form results in decreased susceptibility to Pilocarpine |
CTD |
PMID:15196965 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
increases response to substance |
ISO |
BDKRB2 protein mutant form results in increased susceptibility to Pilocarpine |
CTD |
PMID:15196965 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression decreases expression multiple interactions |
ISO EXP |
Pilocarpine results in increased expression of BDNF protein modified form Pilocarpine results in increased expression of BDNF exon; Pilocarpine results in increased expression of BDNF mRNA; Pilocarpine results in increased expression of BDNF mRNA alternative form; Pilocarpine results in increased expression of BDNF protein Pilocarpine results in decreased expression of BDNF protein 1 alpha,24-dihydroxyvitamin D3 inhibits the reaction [Pilocarpine results in increased expression of BDNF mRNA]; 1 alpha,24-dihydroxyvitamin D3 promotes the reaction [Pilocarpine results in increased expression of BDNF mRNA]; 6-Cyano-7-nitroquinoxaline-2,3-dione inhibits the reaction [Pilocarpine results in increased expression of BDNF mRNA alternative form]; [Diazepam co-treated with Pentobarbital] promotes the reaction [Pilocarpine results in increased expression of BDNF mRNA]; [Pilocarpine co-treated with Diazepam co-treated with Pentobarbital] results in increased expression of BDNF protein; BDNF inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; Diazepam inhibits the reaction [Pilocarpine results in increased expression of BDNF mRNA]; Dizocilpine Maleate inhibits the reaction [Pilocarpine results in increased expression of and results in increased localization of BDNF mRNA]; Ketamine inhibits the reaction [Pilocarpine results in increased expression of BDNF mRNA]; Paraldehyde promotes the reaction [Pilocarpine results in increased expression of BDNF mRNA]; Pilocarpine promotes the reaction [BDNF protein results in decreased expression of NTRK2 protein]; Pilocarpine results in increased expression of and results in increased localization of BDNF mRNA; Pilocarpine results in increased expression of and results in increased localization of BDNF protein; Scopolamine inhibits the reaction [Pilocarpine results in increased expression of BDNF mRNA] |
CTD |
PMID:8405262 PMID:8635431 PMID:8821376 PMID:9015327 PMID:9073163 PMID:11259499 PMID:12231234 PMID:14656328 PMID:15183516 PMID:15282290 PMID:15781040 PMID:19397936 PMID:19686240 PMID:21087489 More...
|
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
EXP |
Vitamin E inhibits the reaction [Pilocarpine results in increased expression of BECN1 mRNA]; Vitamin E inhibits the reaction [Pilocarpine results in increased expression of BECN1 protein] Pilocarpine results in increased expression of BECN1 mRNA; Pilocarpine results in increased expression of BECN1 protein |
CTD |
PMID:17971868 PMID:19138675 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of BMP4 mRNA Pilocarpine results in increased expression of BMP4 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bnip1 |
BCL2 interacting protein 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of BNIP1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of BNIP3 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
decreases expression increases expression |
ISO |
Pilocarpine results in decreased expression of CACNA1A protein Pilocarpine results in increased expression of CACNA1A protein |
CTD |
PMID:17265461 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1b |
calcium voltage-gated channel subunit alpha1 B |
decreases expression increases expression |
ISO |
Pilocarpine results in decreased expression of CACNA1B mRNA; Pilocarpine results in decreased expression of CACNA1B protein Pilocarpine results in increased expression of CACNA1B protein |
CTD |
PMID:19811616 |
|
NCBI chr 3:7,380,892...7,546,104
Ensembl chr 3:7,380,922...7,546,091
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
decreases expression increases expression |
ISO |
Pilocarpine results in decreased expression of CACNA1C protein Pilocarpine results in increased expression of CACNA1C protein |
CTD |
PMID:17265461 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Cacna1d |
calcium voltage-gated channel subunit alpha1 D |
decreases expression increases expression |
ISO |
Pilocarpine results in decreased expression of CACNA1D protein Pilocarpine results in increased expression of CACNA1D protein |
CTD |
PMID:17265461 |
|
NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
EXP |
[Pilocarpine co-treated with Lithium] results in increased expression of CASP12 mRNA; [Pilocarpine co-treated with Lithium] results in increased expression of CASP12 protein; Edaravone inhibits the reaction [[Pilocarpine co-treated with Lithium] results in increased expression of CASP12 protein] |
CTD |
PMID:21429313 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity increases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Pilocarpine results in increased activity of CASP3 protein]; 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Pilocarpine results in increased activity of CASP3 protein]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Pilocarpine results in increased activity of CASP3 protein]; Verapamil inhibits the reaction [Pilocarpine results in increased activity of CASP3 protein] [Pilocarpine co-treated with Lithium] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Pilocarpine results in increased cleavage of CASP3 protein]; Dizocilpine Maleate inhibits the reaction [Pilocarpine results in increased cleavage of CASP3 protein]; Pilocarpine results in increased cleavage of and results in increased activity of CASP3 protein; Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased activity of CASP3 protein]; Thioctic Acid inhibits the reaction [Pilocarpine results in increased activity of CASP3 protein] ZFP110 protein mutant form inhibits the reaction [Pilocarpine results in increased cleavage of CASP3 protein] Pilocarpine results in increased expression of CASP3 protein modified form |
CTD |
PMID:12097334 PMID:18708038 PMID:18815271 PMID:19429016 PMID:19631748 PMID:19927300 PMID:20149694 PMID:21062633 PMID:22824136 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
EXP |
Pilocarpine results in increased cleavage of and results in increased activity of CASP6 protein |
CTD |
PMID:12097334 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Pilocarpine results in increased expression of CASP9 protein |
CTD |
PMID:18708038 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity increases expression multiple interactions |
ISO EXP |
Pilocarpine results in increased activity of CAT protein Pilocarpine results in increased expression of CAT protein 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Pilocarpine results in increased expression of CAT protein]; Nimodipine inhibits the reaction [Pilocarpine results in increased expression of CAT protein] Levetiracetam inhibits the reaction [Pilocarpine results in increased activity of CAT protein] |
CTD |
PMID:15245787 PMID:15752349 PMID:16115668 PMID:17205390 PMID:17383094 PMID:18242586 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression decreases expression |
EXP ISO |
Pilocarpine results in increased expression of CCL2 mRNA; Pilocarpine results in increased expression of CCL2 protein Pilocarpine results in decreased expression of CCL2 protein |
CTD |
PMID:15193289 PMID:17971868 PMID:19490431 PMID:20034406 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression increases expression |
ISO |
Pilocarpine results in decreased expression of CCL3 protein Pilocarpine results in increased expression of CCL3 mRNA |
CTD |
PMID:19490431 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccr10 |
C-C motif chemokine receptor 10 |
decreases expression |
ISO |
Pilocarpine results in decreased expression of CCR10 mRNA; Pilocarpine results in decreased expression of CCR10 protein |
CTD |
PMID:17181556 |
|
NCBI chr10:86,108,551...86,110,988
Ensembl chr10:86,108,551...86,110,988
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression decreases expression |
EXP ISO |
Pilocarpine results in increased expression of CCR2 protein Pilocarpine results in decreased expression of CCR2 mRNA; Pilocarpine results in decreased expression of CCR2 protein |
CTD |
PMID:19490431 PMID:20034406 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr3 |
C-C motif chemokine receptor 3 |
decreases expression |
ISO |
Pilocarpine results in decreased expression of CCR3 mRNA; Pilocarpine results in decreased expression of CCR3 protein |
CTD |
PMID:19490431 |
|
NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
decreases expression |
ISO |
Pilocarpine results in decreased expression of CCR7 mRNA; Pilocarpine results in decreased expression of CCR7 protein |
CTD |
PMID:17181556 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
decreases expression |
ISO |
Pilocarpine results in decreased expression of CCR8 mRNA; Pilocarpine results in decreased expression of CCR8 protein |
CTD |
PMID:17181556 |
|
NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629
|
|
G |
Ccr9 |
C-C motif chemokine receptor 9 |
decreases expression |
ISO |
Pilocarpine results in decreased expression of CCR9 mRNA; Pilocarpine results in decreased expression of CCR9 protein |
CTD |
PMID:17181556 |
|
NCBI chr 8:123,396,157...123,410,199
Ensembl chr 8:123,395,813...123,413,969
|
|
G |
Cd40 |
CD40 molecule |
increases expression multiple interactions |
EXP |
Pilocarpine results in increased expression of CD40 protein rosiglitazone inhibits the reaction [Pilocarpine results in increased expression of CD40 protein] |
CTD |
PMID:18455351 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
ISO |
Pilocarpine results in increased expression of CD44 protein |
CTD |
PMID:15191797 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of CDH1 protein Pilocarpine results in increased expression of CDH1 protein |
CTD |
PMID:12387456 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of CDH2 mRNA; Pilocarpine results in increased expression of CDH2 protein |
CTD |
PMID:12125071 PMID:12387456 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of CDK1 mRNA |
CTD |
PMID:14656328 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of CDK2 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
Pilocarpine results in increased expression of CDKN1B mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of CDKN2A mRNA Pilocarpine results in increased expression of CDKN2A mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of CEBPA mRNA] |
CTD |
PMID:32494933 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chat |
choline O-acetyltransferase |
decreases activity multiple interactions decreases expression |
EXP |
Pilocarpine results in decreased activity of CHAT protein [Thioctic Acid co-treated with Pilocarpine] results in increased activity of CHAT protein Pilocarpine results in decreased expression of CHAT protein |
CTD |
PMID:19669875 PMID:19932735 PMID:19941057 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions increases expression affects binding decreases expression increases activity affects response to substance |
ISO EXP |
[Pilocarpine results in increased activity of CHRM1 protein] which results in increased abundance of Calcium; brucine promotes the reaction [Pilocarpine binds to CHRM1 protein] Pilocarpine results in increased expression of CHRM1 protein CHRM1 protein binds to Pilocarpine Pilocarpine results in decreased expression of CHRM1 protein Pilocarpine inhibits the reaction [N-Methylscopolamine binds to CHRM1 protein]; Pilocarpine promotes the reaction [N-Methylscopolamine binds to CHRM1 protein] CHRM1 protein mutant form inhibits the reaction [Pilocarpine results in increased hydrolysis of Phosphatidylinositols] CHRM1 protein affects the susceptibility to Pilocarpine |
CTD |
PMID:9224827 PMID:11527950 PMID:12713643 PMID:14559291 PMID:15967574 PMID:16137708 PMID:16563474 PMID:32234387 More...
|
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
decreases expression increases expression multiple interactions affects binding |
EXP ISO |
Pilocarpine results in decreased expression of CHRM2 protein Pilocarpine results in increased expression of CHRM2 protein eburnamonine promotes the reaction [Pilocarpine binds to CHRM2 protein] CHRM2 protein binds to Pilocarpine Pilocarpine promotes the reaction [N-Methylscopolamine binds to CHRM2 protein] |
CTD |
PMID:9224827 PMID:14559291 PMID:32234387 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions increases expression affects binding |
ISO |
brucine promotes the reaction [Pilocarpine binds to CHRM3 protein] Pilocarpine results in increased expression of CHRM3 protein CHRM3 protein binds to Pilocarpine |
CTD |
PMID:9224827 PMID:32234387 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions increases expression affects binding |
EXP ISO |
Pilocarpine binds to and results in increased activity of CHRM4 protein Pilocarpine results in increased expression of CHRM4 protein CHRM4 protein binds to Pilocarpine brucine promotes the reaction [Pilocarpine binds to CHRM4 protein]; eburnamonine promotes the reaction [Pilocarpine binds to CHRM4 protein] |
CTD |
PMID:9224827 PMID:9920179 PMID:32234387 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
increases expression |
ISO |
Pilocarpine results in increased expression of CHRM5 protein |
CTD |
PMID:32234387 |
|
NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252
|
|
G |
Cib1 |
calcium and integrin binding 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of CIB1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:134,178,331...134,183,895
Ensembl chr 1:134,178,331...134,213,423
|
|
G |
Clcn2 |
chloride voltage-gated channel 2 |
affects expression |
EXP |
Pilocarpine affects the expression of CLCN2 protein |
CTD |
PMID:16930566 |
|
NCBI chr11:80,197,741...80,211,657
Ensembl chr11:80,198,153...80,211,657
|
|
G |
Cnn3 |
calponin 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of CNN3 protein |
CTD |
PMID:14620880 |
|
NCBI chr 2:209,518,948...209,550,107
Ensembl chr 2:209,518,948...209,550,104
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of CNR1 protein |
CTD |
PMID:19368833 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cntf |
ciliary neurotrophic factor |
increases expression |
EXP |
Pilocarpine results in increased expression of CNTF mRNA |
CTD |
PMID:10506506 |
|
NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of CSF2 mRNA Pilocarpine results in increased expression of CSF2 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
increases expression |
EXP |
Pilocarpine results in increased expression of CSF2RB mRNA |
CTD |
PMID:17166730 |
|
NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157
|
|
G |
Csn2 |
casein beta |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of CSN2 mRNA Pilocarpine results in increased expression of CSN2 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr14:20,322,581...20,329,818
Ensembl chr14:20,322,581...20,329,817
|
|
G |
Ctf1 |
cardiotrophin 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of CTF1 mRNA |
CTD |
PMID:10506506 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of CTNNB1 protein |
CTD |
PMID:12387456 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
increases expression |
EXP |
Pilocarpine results in increased expression of CTSD mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of CYP11A1 protein |
CTD |
PMID:19125849 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Dap3 |
death associated protein 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of DAP3 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461
|
|
G |
Dclre1a |
DNA cross-link repair 1A |
increases expression |
EXP |
Pilocarpine results in increased expression of DCLRE1A mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:255,569,911...255,589,815
Ensembl chr 1:255,569,919...255,589,678
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of DDIT3 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dmd |
dystrophin |
decreases expression |
EXP |
Pilocarpine results in decreased expression of DMD protein |
CTD |
PMID:20886625 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of DPYSL2 protein |
CTD |
PMID:17366478 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Drd1 |
dopamine receptor D1 |
increases expression decreases expression multiple interactions increases response to substance |
EXP ISO |
Pilocarpine results in increased expression of DRD1 mRNA Pilocarpine results in decreased expression of DRD1 protein Pilocarpine inhibits the reaction [SCH 23390 binds to DRD1 protein] DRD1 protein results in increased susceptibility to Pilocarpine [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased susceptibility to Pilocarpine; [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Dizocilpine Maleate] co-treated with [1-hydroxy-3-amino-2-pyrrolidone results in increased activity of DRD1 protein]] results in increased susceptibility to Pilocarpine |
CTD |
PMID:1365435 PMID:7906944 PMID:14656328 PMID:15876489 PMID:16137708 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions decreases expression decreases response to substance decreases activity |
EXP ISO |
[[Remoxipride results in decreased activity of DRD2 protein] co-treated with [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide results in decreased activity of HTR1A protein]] results in increased susceptibility to Pilocarpine; [Remoxipride results in decreased activity of DRD2 protein] inhibits the reaction [Dopamine results in decreased susceptibility to Pilocarpine]; Pilocarpine inhibits the reaction [Spiperone binds to DRD2 protein]; Pilocarpine promotes the reaction [Spiperone binds to DRD2 protein] Pilocarpine results in decreased expression of DRD2 protein DRD2 protein results in decreased susceptibility to Pilocarpine Pilocarpine results in decreased activity of DRD2 protein |
CTD |
PMID:1365435 PMID:11860278 PMID:14559291 PMID:15140183 PMID:15876489 PMID:16137708 More...
|
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Efna3 |
ephrin A3 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of EFNA3 mRNA |
CTD |
PMID:18772502 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
EXP |
Pilocarpine results in decreased expression of EGFR mRNA |
CTD |
PMID:17971868 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
EXP |
Pilocarpine results in increased expression of EGR1 mRNA Atropine inhibits the reaction [Pilocarpine results in increased expression of EGR1 mRNA]; Pirenzepine inhibits the reaction [Pilocarpine results in increased expression of EGR1 mRNA] |
CTD |
PMID:7968354 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions increases expression |
EXP |
Atropine inhibits the reaction [Pilocarpine results in increased expression of EGR2 mRNA]; Pirenzepine inhibits the reaction [Pilocarpine results in increased expression of EGR2 mRNA] |
CTD |
PMID:7968354 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Egr3 |
early growth response 3 |
multiple interactions increases expression |
EXP |
Pilocarpine promotes the reaction [EGR3 protein binds to GABRA4 promoter] Pilocarpine results in increased expression of EGR3 mRNA; Pilocarpine results in increased expression of EGR3 protein |
CTD |
PMID:16091474 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
decreases expression |
EXP |
Pilocarpine results in decreased expression of EI24 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions |
ISO |
Pilocarpine promotes the reaction [EIF2AK2 protein modified form results in increased phosphorylation of EIF2S1 protein]; Pilocarpine results in increased phosphorylation of and results in increased activity of EIF2AK2 protein |
CTD |
PMID:16492139 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases activity |
ISO |
Pilocarpine promotes the reaction [EIF2AK3 protein modified form results in increased phosphorylation of EIF2S1 protein] Pilocarpine results in increased activity of EIF2AK3 protein |
CTD |
PMID:16492139 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
Pilocarpine promotes the reaction [EIF2AK2 protein modified form results in increased phosphorylation of EIF2S1 protein]; Pilocarpine promotes the reaction [EIF2AK3 protein modified form results in increased phosphorylation of EIF2S1 protein]; Pilocarpine promotes the reaction [EIF2S1 protein modified form results in decreased expression of ACTB protein]; Pilocarpine promotes the reaction [EIF2S1 protein modified form results in decreased expression of RPL32 protein] Pilocarpine results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:15003282 PMID:16492139 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Epha5 |
EPH receptor A5 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of EPHA5 mRNA; Pilocarpine results in decreased expression of EPHA5 protein |
CTD |
PMID:18772502 |
|
NCBI chr14:23,653,393...24,020,129
Ensembl chr14:23,653,393...24,017,317
|
|
G |
Epo |
erythropoietin |
increases expression |
EXP |
Pilocarpine results in increased expression of EPO mRNA |
CTD |
PMID:17166730 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epor |
erythropoietin receptor |
increases expression |
EXP |
Pilocarpine results in increased expression of EPOR mRNA |
CTD |
PMID:17166730 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
increases expression |
EXP |
Pilocarpine results in increased expression of ERCC1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc3 |
ERCC excision repair 3, TFIIH core complex helicase subunit |
increases expression |
EXP |
Pilocarpine results in increased expression of ERCC3 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329
|
|
G |
Ezr |
ezrin |
increases expression |
EXP |
Pilocarpine results in increased expression of EZR protein |
CTD |
PMID:17366478 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F2 |
coagulation factor II, thrombin |
increases activity |
ISO |
Pilocarpine results in increased activity of F2 protein |
CTD |
PMID:30515700 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
FGF2 inhibits the reaction [Pilocarpine results in increased expression of IL1B protein] |
CTD |
PMID:21087489 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
increases expression |
EXP |
Pilocarpine results in increased expression of FGF5 mRNA |
CTD |
PMID:8167846 |
|
NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression increases expression |
EXP |
[Pilocarpine co-treated with 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine] results in increased expression of FOS protein; [Pilocarpine co-treated with Lithium] results in increased expression of FOS protein; [Pilocarpine co-treated with SCH 23390] results in increased expression of FOS protein; Atropine inhibits the reaction [Pilocarpine results in increased expression of FOS mRNA]; Diazepam inhibits the reaction [Pilocarpine results in increased expression of FOS mRNA]; Dizocilpine Maleate inhibits the reaction [Pilocarpine results in increased expression of FOS mRNA]; Lithium promotes the reaction [Pilocarpine results in increased expression of FOS mRNA]; Pirenzepine inhibits the reaction [Pilocarpine results in increased expression of FOS mRNA] Pilocarpine results in decreased expression of FOS mRNA Pilocarpine results in increased expression of FOS mRNA; Pilocarpine results in increased expression of FOS protein |
CTD |
PMID:7713058 PMID:7968354 PMID:7984056 PMID:8281324 PMID:8511714 PMID:9630518 PMID:17971868 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Pilocarpine results in increased expression of FOSB protein |
CTD |
PMID:16391389 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
decreases expression |
EXP |
Pilocarpine results in decreased expression of FSHB protein |
CTD |
PMID:9761326 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions decreases expression |
EXP |
bacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRA1 mRNA]; Carbamazepine inhibits the reaction [Pilocarpine results in decreased expression of GABRA1 mRNA] |
CTD |
PMID:20821261 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
increases expression multiple interactions |
ISO EXP |
Pilocarpine results in increased expression of GABRA4 protein Pilocarpine results in increased expression of GABRA4 mRNA Pilocarpine promotes the reaction [EGR3 protein binds to GABRA4 promoter] |
CTD |
PMID:15456836 PMID:16091474 |
|
NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
|
|
G |
Gabra5 |
gamma-aminobutyric acid type A receptor subunit alpha 5 |
multiple interactions decreases expression |
EXP |
bacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA]; Carbamazepine inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA] |
CTD |
PMID:20821261 |
|
NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917
|
|
G |
Gabrd |
gamma-aminobutyric acid type A receptor subunit delta |
multiple interactions decreases expression |
EXP ISO |
bacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRD mRNA]; Carbamazepine inhibits the reaction [Pilocarpine results in decreased expression of GABRD mRNA] Pilocarpine results in decreased expression of GABRD protein |
CTD |
PMID:15456836 PMID:20821261 |
|
NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:165,958,484...165,970,411
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
increases expression |
ISO |
Pilocarpine results in increased expression of GABRG2 protein |
CTD |
PMID:15456836 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of GAD1 mRNA |
CTD |
PMID:16797850 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
affects expression increases expression decreases expression |
EXP |
Pilocarpine affects the expression of GAD2 protein Pilocarpine results in increased expression of GAD2 mRNA; Pilocarpine results in increased expression of GAD2 protein Pilocarpine results in decreased expression of GAD2 protein |
CTD |
PMID:12183020 PMID:15857427 PMID:15987249 PMID:16797850 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gap43 |
growth associated protein 43 |
decreases expression increases expression |
ISO EXP |
Pilocarpine results in decreased expression of GAP43 protein Pilocarpine results in increased expression of GAP43 mRNA |
CTD |
PMID:15191797 PMID:16134595 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression multiple interactions |
EXP |
Pilocarpine results in increased expression of GDNF mRNA [Lithium co-treated with Pilocarpine] results in increased expression of GDNF protein |
CTD |
PMID:7854063 PMID:12914250 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions increases expression decreases expression |
EXP |
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC promotes the reaction [Pilocarpine results in increased expression of GFAP protein]; [Lithium Chloride co-treated with Pilocarpine] results in increased expression of GFAP mRNA; [Lithium Chloride co-treated with Pilocarpine] results in increased expression of GFAP protein; iodopravadoline inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC promotes the reaction [Pilocarpine results in increased expression of GFAP protein]] Pilocarpine results in decreased expression of GFAP protein |
CTD |
PMID:25101675 PMID:30542433 PMID:31018114 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression affects localization |
EXP |
Pilocarpine results in increased expression of GJA1 protein Pilocarpine affects the localization of GJA1 protein |
CTD |
PMID:21177194 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in decreased expression of GLUD1 mRNA]; [Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in decreased expression of GLUD2 mRNA] |
CTD |
PMID:32494933 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
EXP |
Pilocarpine results in decreased expression of GLUL protein |
CTD |
PMID:25101675 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion |
ISO |
Pilocarpine results in increased secretion of GPT protein |
CTD |
PMID:32234387 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of GRIA1 mRNA Pilocarpine results in increased expression of GRIA1 protein |
CTD |
PMID:7529610 PMID:15857427 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions decreases expression increases expression |
EXP |
[Lithium co-treated with Pilocarpine] results in increased expression of GRIA2 mRNA Pilocarpine results in decreased expression of GRIA2 mRNA Pilocarpine results in increased expression of GRIA2 3' UTR alternative form; Pilocarpine results in increased expression of GRIA2 protein |
CTD |
PMID:15857427 PMID:16819974 PMID:19222700 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
multiple interactions increases expression decreases expression |
EXP |
[Lithium co-treated with Pilocarpine] results in decreased expression of GRIA3 mRNA Pilocarpine results in increased expression of GRIA3 mRNA; Pilocarpine results in increased expression of GRIA3 protein Pilocarpine results in decreased expression of GRIA3 mRNA |
CTD |
PMID:7529610 PMID:15857427 PMID:16819974 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Grik1 |
glutamate ionotropic receptor kainate type subunit 1 |
multiple interactions |
EXP |
[Excitatory Amino Acid Antagonists binds to and results in decreased activity of GRIK1 protein] which results in decreased susceptibility to Pilocarpine |
CTD |
PMID:12080343 |
|
NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
multiple interactions |
EXP |
[Lithium co-treated with Pilocarpine] results in increased expression of GRIK2 mRNA |
CTD |
PMID:16819974 |
|
NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
multiple interactions |
EXP |
[Lithium co-treated with Pilocarpine] results in decreased expression of GRIK5 mRNA |
CTD |
PMID:16819974 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions decreases expression |
EXP |
Plant Preparations inhibits the reaction [Pilocarpine results in decreased expression of GRIN1 mRNA] |
CTD |
PMID:18086456 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions increases expression decreases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Pilocarpine results in increased expression of GRIN2A protein]; [Lithium co-treated with Pilocarpine] results in increased phosphorylation of GRIN2A protein; ifenprodil inhibits the reaction [Pilocarpine results in increased expression of GRIN2A protein] Pilocarpine results in decreased expression of GRIN2A protein |
CTD |
PMID:15857427 PMID:16600505 PMID:22824136 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
decreases expression increases expression multiple interactions |
EXP |
Pilocarpine results in decreased expression of GRIN2B protein Pilocarpine results in increased expression of GRIN2B protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Pilocarpine results in increased expression of GRIN2B protein]; [Lithium co-treated with Pilocarpine] results in increased phosphorylation of GRIN2B protein; Acetylcysteine inhibits the reaction [Pilocarpine results in increased expression of GRIN2B protein]; ifenprodil inhibits the reaction [Pilocarpine results in increased expression of GRIN2B protein] |
CTD |
PMID:15857427 PMID:16600505 PMID:22824136 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
decreases expression multiple interactions increases expression |
EXP |
Pilocarpine results in decreased expression of GRM1 protein [Dexamethasone co-treated with Lithium Chloride co-treated with Pilocarpine] affects the expression of GRM1 mRNA Pilocarpine results in increased expression of GRM1 protein |
CTD |
PMID:11463519 PMID:32494933 |
|
NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
|
|
G |
Grm2 |
glutamate metabotropic receptor 2 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of GRM2 mRNA; Pilocarpine results in decreased expression of GRM2 protein |
CTD |
PMID:16793029 PMID:18585369 PMID:18804094 |
|
NCBI chr 8:107,280,099...107,293,159
Ensembl chr 8:107,280,099...107,293,146
|
|
G |
Grm3 |
glutamate metabotropic receptor 3 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of GRM3 mRNA; Pilocarpine results in decreased expression of GRM3 protein |
CTD |
PMID:16793029 PMID:18585369 PMID:18804094 |
|
NCBI chr 4:24,364,854...24,643,972
Ensembl chr 4:24,365,115...24,609,804
|
|
G |
Grm5 |
glutamate metabotropic receptor 5 |
multiple interactions decreases expression |
EXP |
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] which results in decreased susceptibility to Pilocarpine Pilocarpine results in decreased expression of GRM5 mRNA; Pilocarpine results in decreased expression of GRM5 protein |
CTD |
PMID:15009663 PMID:17634364 |
|
NCBI chr 1:141,310,069...141,884,980
Ensembl chr 1:141,312,368...141,882,274
|
|
G |
Grm8 |
glutamate metabotropic receptor 8 |
increases expression decreases expression |
EXP |
Pilocarpine results in increased expression of GRM8 protein Pilocarpine results in decreased expression of GRM8 |
CTD |
PMID:11226630 PMID:12539201 |
|
NCBI chr 4:55,805,762...56,731,690
Ensembl chr 4:55,805,955...56,730,831
|
|
G |
Hcn1 |
hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 |
multiple interactions decreases expression |
EXP |
[Pilocarpine co-treated with Diazepam] results in increased expression of HCN1 mRNA Pilocarpine results in decreased expression of HCN1 protein |
CTD |
PMID:12890777 PMID:21905079 |
|
NCBI chr 2:49,495,771...49,899,983
Ensembl chr 2:49,495,771...49,899,774
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
EXP |
Pilocarpine results in increased expression of HIF1A mRNA |
CTD |
PMID:17166730 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of HK2 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of HMGB1 mRNA]; [Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of HMGB1 protein] |
CTD |
PMID:32494933 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP ISO |
Pilocarpine results in increased expression of HMOX1 protein Pilocarpine results in increased expression of HMOX1 mRNA |
CTD |
PMID:20971094 PMID:25715797 PMID:32234387 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxb1 |
homeo box B1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of HOXB1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr10:81,331,507...81,332,928
Ensembl chr10:81,331,507...81,332,836
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
decreases expression |
EXP |
Pilocarpine results in decreased expression of HRK mRNA |
CTD |
PMID:17971868 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hsbp1 |
heat shock factor binding protein 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of HSBP1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr19:47,401,039...47,405,373
Ensembl chr19:47,400,966...47,435,821
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
[Pilocarpine co-treated with Lithium] results in increased expression of HSPA5 mRNA; [Pilocarpine co-treated with Lithium] results in increased expression of HSPA5 protein; Edaravone promotes the reaction [[Pilocarpine co-treated with Lithium] results in increased expression of HSPA5 protein] |
CTD |
PMID:21429313 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of HSPB1 mRNA; Pilocarpine results in increased expression of HSPB1 protein |
CTD |
PMID:17971868 PMID:20971094 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
[8-Hydroxy-2-(di-n-propylamino)tetralin results in increased activity of HTR1A protein] which results in decreased susceptibility to Pilocarpine; [[Remoxipride results in decreased activity of DRD2 protein] co-treated with [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide results in decreased activity of HTR1A protein]] results in increased susceptibility to Pilocarpine |
CTD |
PMID:2533336 PMID:15140183 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
EXP |
[cyanopindolol results in decreased activity of HTR1B protein] which results in decreased susceptibility to Pilocarpine |
CTD |
PMID:2533336 |
|
NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
multiple interactions increases expression decreases expression |
EXP |
Carbamazepine inhibits the reaction [Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]]; Carbamazepine inhibits the reaction [Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]]; Carbamazepine inhibits the reaction [Pilocarpine results in decreased expression of HTR2C mRNA]; Carbamazepine inhibits the reaction [Pilocarpine results in decreased expression of HTR2C protein]; Carbamazepine inhibits the reaction [Pilocarpine results in increased expression of HTR2C mRNA]; Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]; Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]; Plant Extracts inhibits the reaction [Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]]; Plant Extracts inhibits the reaction [Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]]; Plant Extracts inhibits the reaction [Pilocarpine results in decreased expression of HTR2C mRNA]; Plant Extracts inhibits the reaction [Pilocarpine results in decreased expression of HTR2C protein]; Plant Extracts inhibits the reaction [Pilocarpine results in increased expression of HTR2C mRNA] Pilocarpine results in increased expression of HTR2C mRNA; Pilocarpine results in increased expression of HTR2C protein Pilocarpine results in decreased expression of HTR2C mRNA; Pilocarpine results in decreased expression of HTR2C protein |
CTD |
PMID:19439326 PMID:19700373 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression |
EXP |
1 alpha,24-dihydroxyvitamin D3 inhibits the reaction [Pilocarpine results in decreased expression of IFNG protein] |
CTD |
PMID:15781040 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of IGFBP3 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Il10 |
interleukin 10 |
multiple interactions decreases expression increases expression |
EXP |
1 alpha,24-dihydroxyvitamin D3 inhibits the reaction [Pilocarpine results in decreased expression of IL10 protein] Pilocarpine results in increased expression of IL10 protein |
CTD |
PMID:15781040 PMID:17872965 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Pilocarpine results in increased expression of IL12B mRNA |
CTD |
PMID:15193289 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression decreases expression |
ISO EXP |
[Pilocarpine co-treated with Lithium] results in increased expression of IL1B mRNA; [Pilocarpine co-treated with Lithium] results in increased expression of IL1B protein; Edaravone inhibits the reaction [[Pilocarpine co-treated with Lithium] results in increased expression of IL1B mRNA]; Edaravone inhibits the reaction [[Pilocarpine co-treated with Lithium] results in increased expression of IL1B protein] Pilocarpine results in increased expression of IL1B mRNA; Pilocarpine results in increased expression of IL1B protein Pilocarpine results in decreased expression of IL1B mRNA [Lithium Chloride co-treated with Pilocarpine] results in increased expression of IL1B mRNA; [Lithium Chloride co-treated with Pilocarpine] results in increased expression of IL1B protein; BDNF inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; FGF2 inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [Pilocarpine results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B protein] |
CTD |
PMID:19010416 PMID:19055492 PMID:19951488 PMID:21087489 PMID:23211629 PMID:31018114 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of IL2 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4r |
interleukin 4 receptor |
increases expression |
EXP |
Pilocarpine results in increased expression of IL4R mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
EXP |
Pilocarpine results in decreased expression of IL6 mRNA [Lithium Chloride co-treated with Pilocarpine] results in increased expression of IL6 mRNA; [Lithium Chloride co-treated with Pilocarpine] results in increased expression of IL6 protein |
CTD |
PMID:19055492 PMID:31018114 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilk |
integrin-linked kinase |
decreases activity |
ISO |
Pilocarpine results in decreased activity of ILK protein |
CTD |
PMID:19631748 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G |
Impa1 |
inositol monophosphatase 1 |
increases response to substance decreases response to substance affects response to substance |
ISO |
IMPA1 gene mutant form results in increased susceptibility to Pilocarpine IMPA1 protein results in decreased susceptibility to Pilocarpine IMPA1 protein affects the susceptibility to Pilocarpine |
CTD |
PMID:17460611 PMID:17602744 PMID:19754464 |
|
NCBI chr 2:91,462,781...91,484,057
Ensembl chr 2:91,462,799...91,484,313
|
|
G |
Itga1 |
integrin subunit alpha 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of ITGA1 protein |
CTD |
PMID:12851778 |
|
NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238
|
|
G |
Itga2 |
integrin subunit alpha 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of ITGA2 protein |
CTD |
PMID:12851778 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itga4 |
integrin subunit alpha 4 |
increases expression |
EXP |
Pilocarpine results in increased expression of ITGA4 protein |
CTD |
PMID:12851778 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Itga5 |
integrin subunit alpha 5 |
increases expression |
EXP |
Pilocarpine results in increased expression of ITGA5 protein |
CTD |
PMID:12851778 |
|
NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression increases expression |
ISO EXP |
Pilocarpine results in decreased expression of ITGB1 protein Pilocarpine results in increased expression of ITGB1 protein |
CTD |
PMID:12851778 PMID:19631748 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb3 |
integrin subunit beta 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of ITGB3 protein |
CTD |
PMID:12851778 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itgb4 |
integrin subunit beta 4 |
increases expression |
EXP |
Pilocarpine results in increased expression of ITGB4 protein |
CTD |
PMID:12851778 |
|
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
[Lithium co-treated with Pilocarpine] results in increased expression of JUN protein; Diazepam inhibits the reaction [Pilocarpine results in increased expression of JUN mRNA]; Dizocilpine Maleate inhibits the reaction [Pilocarpine results in increased expression of JUN mRNA]; Lithium promotes the reaction [Pilocarpine results in increased expression of JUN mRNA] |
CTD |
PMID:7984056 PMID:17971868 PMID:19430551 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
Atropine inhibits the reaction [Pilocarpine results in increased expression of JUNB mRNA]; Diazepam inhibits the reaction [Pilocarpine results in increased expression of JUNB mRNA]; Dizocilpine Maleate inhibits the reaction [Pilocarpine results in increased expression of JUNB mRNA]; Lithium promotes the reaction [Pilocarpine results in increased expression of JUNB mRNA]; Pirenzepine inhibits the reaction [Pilocarpine results in increased expression of JUNB mRNA] |
CTD |
PMID:7968354 PMID:7984056 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of KCNC4 mRNA; Pilocarpine results in decreased expression of KCNC4 protein |
CTD |
PMID:20971086 |
|
NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233
|
|
G |
Kcnk5 |
potassium two pore domain channel subfamily K member 5 |
increases expression decreases expression |
EXP |
Pilocarpine results in increased expression of KCNK5 protein Pilocarpine results in decreased expression of KCNK5 protein |
CTD |
PMID:19220408 |
|
NCBI chr15:4,122,442...4,164,718
Ensembl chr15:4,122,442...4,164,718
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of KCNMA1 mRNA |
CTD |
PMID:18695509 |
|
NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198
|
|
G |
Kcnn1 |
potassium calcium-activated channel subfamily N member 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of KCNN1 protein |
CTD |
PMID:20553876 |
|
NCBI chr16:18,574,858...18,598,585
Ensembl chr16:18,585,992...18,597,482
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of KCNN2 mRNA; Pilocarpine results in decreased expression of KCNN2 protein |
CTD |
PMID:20553876 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Kcnn3 |
potassium calcium-activated channel subfamily N member 3 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of KCNN3 mRNA; Pilocarpine results in decreased expression of KCNN3 protein |
CTD |
PMID:20553876 |
|
NCBI chr 2:174,929,846...175,088,910
Ensembl chr 2:174,936,629...175,081,145
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions increases expression |
EXP |
Vitamin E inhibits the reaction [Pilocarpine results in increased expression of LAMP2 protein] Pilocarpine results in increased expression of LAMP2 mRNA; Pilocarpine results in increased expression of LAMP2 protein |
CTD |
PMID:19272430 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
Pilocarpine results in decreased expression of LHB protein |
CTD |
PMID:9761326 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
EXP |
Pilocarpine results in increased expression of LIF mRNA |
CTD |
PMID:10506506 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Pilocarpine results in increased phosphorylation of MAPK1 protein Celecoxib inhibits the reaction [Pilocarpine results in increased phosphorylation of MAPK1 protein]; ifenprodil inhibits the reaction [Pilocarpine results in increased phosphorylation of MAPK1 protein] Pilocarpine results in increased phosphorylation of and results in increased activity of MAPK1 protein; PTPN5 protein inhibits the reaction [Pilocarpine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SL 327 inhibits the reaction [Pilocarpine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12091480 PMID:17360923 PMID:18988310 PMID:19402951 PMID:22824136 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
Pilocarpine results in increased phosphorylation of MAPK3 protein Celecoxib inhibits the reaction [Pilocarpine results in increased phosphorylation of MAPK3 protein]; ifenprodil inhibits the reaction [Pilocarpine results in increased phosphorylation of MAPK3 protein] Pilocarpine results in increased phosphorylation of and results in increased activity of MAPK3 protein; PTPN5 protein inhibits the reaction [Pilocarpine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SL 327 inhibits the reaction [Pilocarpine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12091480 PMID:17360923 PMID:18988310 PMID:19402951 PMID:22824136 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases activity |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Pilocarpine results in increased activity of MAPK8 protein]; 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Pilocarpine results in increased activity of MAPK8 protein]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Pilocarpine results in increased activity of MAPK8 protein]; W 7 inhibits the reaction [Pilocarpine results in increased activity of MAPK8 protein] |
CTD |
PMID:19927300 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
increases expression |
EXP |
Pilocarpine results in increased expression of MEF2C mRNA |
CTD |
PMID:18949272 |
|
NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression |
EXP |
Pilocarpine results in increased expression of MGMT mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mir200c |
microRNA 200c |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] results in increased expression of MIR200C mRNA |
CTD |
PMID:31018114 |
|
NCBI chr 4:157,523,679...157,523,747
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity increases expression |
ISO |
Pilocarpine results in increased activity of MMP9 protein Pilocarpine results in increased expression of MMP9 protein |
CTD |
PMID:19631748 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
increases expression |
EXP |
Pilocarpine results in increased expression of MRE11A mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Msn |
moesin |
increases expression |
EXP |
Pilocarpine results in increased expression of MSN mRNA |
CTD |
PMID:14656328 |
|
NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions increases phosphorylation |
EXP |
dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Pilocarpine results in increased phosphorylation of MTOR protein]]; Resveratrol inhibits the reaction [Pilocarpine results in increased phosphorylation of MTOR protein] |
CTD |
PMID:23211629 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression |
EXP |
Pilocarpine results in increased expression of MYD88 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of NAIP2 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
decreases expression |
ISO |
Pilocarpine results in decreased expression of NFAT5 mRNA |
CTD |
PMID:21219332 |
|
NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
Pilocarpine results in increased expression of NFE2L2 protein |
CTD |
PMID:32234387 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression multiple interactions increases phosphorylation |
ISO EXP |
Pilocarpine results in increased expression of NFKBIA mRNA resveratrol inhibits the reaction [Pilocarpine results in increased phosphorylation of NFKBIA protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:15193289 PMID:23211629 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
Ketamine inhibits the reaction [Pilocarpine results in increased expression of NGF mRNA]; Scopolamine inhibits the reaction [Pilocarpine results in increased expression of NGF mRNA] |
CTD |
PMID:8635431 PMID:8821376 PMID:15183516 PMID:17971868 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression multiple interactions increases response to substance |
ISO EXP |
Pilocarpine results in increased expression of NGFR protein Pilocarpine results in increased expression of NGFR mRNA; Pilocarpine results in increased expression of NGFR protein PTEN protein mutant form inhibits the reaction [Pilocarpine results in increased activity of NGFR protein] NGFR protein results in increased susceptibility to Pilocarpine |
CTD |
PMID:10436046 PMID:12097334 PMID:18815271 PMID:21084616 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions increases expression |
EXP |
[Pilocarpine co-treated with Lithium] results in increased expression of NOS1 protein; Edaravone inhibits the reaction [Pilocarpine results in increased expression of NOS1 protein]; Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased expression of NOS1 protein] |
CTD |
PMID:18672383 PMID:20149694 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP |
[Pilocarpine co-treated with Lithium] results in increased expression of NOS2 protein; Edaravone inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein]; Resveratrol inhibits the reaction [Pilocarpine results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein]; Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased expression of NOS2 protein] Pilocarpine results in increased expression of NOS2 mRNA; Pilocarpine results in increased expression of NOS2 protein |
CTD |
PMID:18672383 PMID:20149694 PMID:23211629 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nova1 |
NOVA alternative splicing regulator 1 |
increases expression multiple interactions |
EXP |
Pilocarpine results in increased expression of NOVA1 mRNA Scopolamine inhibits the reaction [Pilocarpine results in increased expression of NOVA1 mRNA] |
CTD |
PMID:20470870 |
|
NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289
|
|
G |
Nova2 |
NOVA alternative splicing regulator 2 |
decreases expression multiple interactions |
EXP |
Pilocarpine results in decreased expression of NOVA2 mRNA Scopolamine inhibits the reaction [Pilocarpine results in decreased expression of NOVA2 mRNA] |
CTD |
PMID:20470870 |
|
NCBI chr 1:78,572,253...78,613,703
Ensembl chr 1:78,572,279...78,608,021
|
|
G |
Nptx2 |
neuronal pentraxin 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of NPTX2 mRNA |
CTD |
PMID:14656328 |
|
NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345
|
|
G |
Npy |
neuropeptide Y |
decreases response to substance increases expression |
ISO EXP |
NPY protein results in decreased susceptibility to Pilocarpine Pilocarpine results in increased expression of NPY protein |
CTD |
PMID:12231234 PMID:12821374 PMID:15451008 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Pilocarpine results in increased expression of NQO1 protein |
CTD |
PMID:32234387 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of NR3C1 mRNA]; [Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of NR3C1 protein] |
CTD |
PMID:32494933 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Ntf3 |
neurotrophin 3 |
decreases expression multiple interactions |
EXP |
Pilocarpine results in decreased expression of NTF3 mRNA Scopolamine inhibits the reaction [Pilocarpine results in decreased expression of NTF3 mRNA] |
CTD |
PMID:8635431 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions increases expression |
EXP |
Ketamine inhibits the reaction [Pilocarpine results in increased expression of NTRK2 mRNA]; Pilocarpine promotes the reaction [BDNF protein results in decreased expression of NTRK2 protein]; Scopolamine inhibits the reaction [Pilocarpine results in increased expression of NTRK2 mRNA] |
CTD |
PMID:8635431 PMID:8821376 PMID:15183516 PMID:19686240 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Ntrk3 |
neurotrophic receptor tyrosine kinase 3 |
increases expression multiple interactions |
EXP |
Pilocarpine results in increased expression of NTRK3 mRNA Scopolamine inhibits the reaction [Pilocarpine results in increased expression of NTRK3 mRNA] |
CTD |
PMID:8635431 |
|
NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of ODC1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression |
EXP |
Pilocarpine results in decreased expression of OGG1 mRNA; Pilocarpine results in decreased expression of OGG1 protein |
CTD |
PMID:20206232 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
decreases response to substance |
ISO |
OPRK1 protein results in decreased susceptibility to Pilocarpine |
CTD |
PMID:7894264 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of OPRM1 protein |
CTD |
PMID:17919468 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Osm |
oncostatin M |
increases expression |
EXP |
Pilocarpine results in increased expression of OSM mRNA |
CTD |
PMID:10506506 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
increases expression |
EXP |
Pilocarpine results in increased expression of P2RX7 protein |
CTD |
PMID:19138473 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
affects expression multiple interactions |
EXP |
Pilocarpine affects the expression of PARP1 protein 3-chloroacetylindole affects the reaction [[Pilocarpine co-treated with Lithium Chloride] affects the expression of PARP1 protein]; [Pilocarpine co-treated with Lithium Chloride] affects the expression of PARP1 protein; bisindolylmaleimide affects the reaction [[Pilocarpine co-treated with Lithium Chloride] affects the expression of PARP1 protein]; U 0126 affects the reaction [[Pilocarpine co-treated with Lithium Chloride] affects the expression of PARP1 protein] |
CTD |
PMID:25101675 PMID:31396050 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP |
Pilocarpine results in increased expression of PCNA mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk1 |
proprotein convertase subtilisin/kexin type 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of PCSK1 mRNA |
CTD |
PMID:9015327 |
|
NCBI chr 2:4,395,543...4,442,434
Ensembl chr 2:4,395,543...4,442,434
|
|
G |
Pdxkl1 |
pyridoxal kinase like 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of PDXK protein |
CTD |
PMID:19356691 |
|
NCBI chr20:10,162,934...10,192,572
Ensembl chr20:10,164,099...10,192,739
|
|
G |
Pea15 |
proliferation and apoptosis adaptor protein 15 |
multiple interactions |
EXP |
[Pilocarpine co-treated with Lithium Chloride co-treated with 3-chloroacetylindole] results in decreased phosphorylation of PEA15 protein; [Pilocarpine co-treated with Lithium Chloride] results in decreased phosphorylation of PEA15 protein |
CTD |
PMID:31396050 |
|
NCBI chr13:84,657,815...84,667,437
Ensembl chr13:84,654,870...84,667,499
|
|
G |
Plcb4 |
phospholipase C, beta 4 |
increases expression |
ISO |
Pilocarpine results in increased expression of PLCB4 protein |
CTD |
PMID:18774262 |
|
NCBI chr 3:122,952,965...123,322,522
Ensembl chr 3:122,953,196...123,322,392
|
|
G |
Pnkp |
polynucleotide kinase 3'-phosphatase |
increases expression |
EXP |
Pilocarpine results in increased expression of PNKP mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:95,341,465...95,346,921
Ensembl chr 1:95,341,620...95,346,920
|
|
G |
Pnpo |
pyridoxamine 5'-phosphate oxidase |
increases expression |
EXP |
Pilocarpine results in increased expression of PNPO protein |
CTD |
PMID:19356691 |
|
NCBI chr10:81,924,584...81,930,844
Ensembl chr10:81,924,569...81,930,871
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
increases expression |
EXP |
Pilocarpine results in increased expression of POLG mRNA; Pilocarpine results in increased expression of POLG protein |
CTD |
PMID:20446108 |
|
NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
Pilocarpine results in increased expression of PPP1R15A protein |
CTD |
PMID:16492139 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Ppp3r1 |
protein phosphatase 3, regulatory subunit B, alpha |
decreases expression |
EXP |
Pilocarpine results in decreased expression of PPP3R1 mRNA |
CTD |
PMID:14656328 |
|
NCBI chr14:91,556,743...91,606,391
Ensembl chr14:91,604,121...91,606,907
|
|
G |
Prkcb |
protein kinase C, beta |
increases expression decreases expression |
ISO EXP |
Pilocarpine results in increased expression of PRKCB protein Pilocarpine results in decreased expression of PRKCB mRNA |
CTD |
PMID:15058486 PMID:17971868 PMID:18774262 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
increases expression |
EXP |
Pilocarpine results in increased expression of PRKCD protein |
CTD |
PMID:15058486 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkcg |
protein kinase C, gamma |
increases expression |
ISO EXP |
Pilocarpine results in increased expression of PRKCG protein |
CTD |
PMID:15058486 PMID:18774262 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Prkch |
protein kinase C, eta |
increases expression |
EXP |
Pilocarpine results in increased expression of PRKCH protein |
CTD |
PMID:15058486 |
|
NCBI chr 6:92,292,000...92,490,663
Ensembl chr 6:92,292,000...92,490,654
|
|
G |
Prkcz |
protein kinase C, zeta |
increases expression |
EXP |
Pilocarpine results in increased expression of PRKCZ protein |
CTD |
PMID:15058486 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
PTEN protein mutant form inhibits the reaction [Pilocarpine results in increased activity of NGFR protein] |
CTD |
PMID:21084616 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptges |
prostaglandin E synthase |
increases expression |
ISO |
Pilocarpine results in increased expression of PTGES mRNA |
CTD |
PMID:15193289 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Pilocarpine results in increased expression of PTGS2 mRNA resveratrol inhibits the reaction [Pilocarpine results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Pilocarpine results in increased expression of PTGS2 protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 protein] Pilocarpine results in increased expression of PTGS2 mRNA; Pilocarpine results in increased expression of PTGS2 protein |
CTD |
PMID:15193289 PMID:23211629 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions increases phosphorylation |
ISO |
[Pilocarpine co-treated with wortmannin] results in increased phosphorylation of PTK2 protein Pilocarpine results in increased phosphorylation of PTK2 protein |
CTD |
PMID:10537051 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
EXP |
[Lithium co-treated with Pilocarpine] results in increased activity of PTK2B protein |
CTD |
PMID:16600505 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
multiple interactions decreases response to substance |
ISO |
PTPN5 protein inhibits the reaction [Pilocarpine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PTPN5 protein inhibits the reaction [Pilocarpine results in increased phosphorylation of and results in increased activity of MAPK3 protein] PTPN5 protein mutant form results in decreased susceptibility to Pilocarpine |
CTD |
PMID:17360923 PMID:21204826 |
|
NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882
|
|
G |
Ptprz1 |
protein tyrosine phosphatase, receptor type Z1 |
affects expression |
EXP |
Pilocarpine affects the expression of PTPRZ1 protein |
CTD |
PMID:10582521 |
|
NCBI chr 4:51,397,316...51,595,220
Ensembl chr 4:51,397,601...51,595,218
|
|
G |
Pvalb |
parvalbumin |
decreases expression |
EXP |
Pilocarpine results in decreased expression of PVALB protein |
CTD |
PMID:12183020 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Qdpr |
quinoid dihydropteridine reductase |
increases expression |
EXP |
Pilocarpine results in increased expression of QDPR protein |
CTD |
PMID:17366478 |
|
NCBI chr14:65,670,251...65,683,853
Ensembl chr14:65,670,131...65,683,854
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
increases expression decreases expression |
EXP |
Pilocarpine results in increased expression of RAD23A mRNA Pilocarpine results in decreased expression of RAD23A mRNA |
CTD |
PMID:17971868 |
|
NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695
|
|
G |
Rad23b |
RAD23 homolog B, nucleotide excision repair protein |
increases expression |
EXP |
Pilocarpine results in increased expression of RAD23B mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 5:70,090,232...70,128,340
Ensembl chr 5:70,090,232...70,128,319
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] results in decreased expression of RECK mRNA; [Lithium Chloride co-treated with Pilocarpine] results in decreased expression of RECK protein |
CTD |
PMID:31018114 |
|
NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
3-chloroacetylindole affects the reaction [[Pilocarpine co-treated with Lithium Chloride] results in increased phosphorylation of RELA protein]; [Pilocarpine co-treated with Lithium Chloride] results in increased phosphorylation of RELA protein; bisindolylmaleimide affects the reaction [[Pilocarpine co-treated with Lithium Chloride] results in increased phosphorylation of RELA protein]; U 0126 affects the reaction [[Pilocarpine co-treated with Lithium Chloride] results in increased phosphorylation of RELA protein] |
CTD |
PMID:31396050 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
EXP |
[Lithium co-treated with Pilocarpine] results in increased expression of RET protein |
CTD |
PMID:12914250 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Rpl32 |
ribosomal protein L32 |
multiple interactions |
ISO |
Pilocarpine promotes the reaction [EIF2S1 protein modified form results in decreased expression of RPL32 protein] |
CTD |
PMID:16492139 |
|
NCBI chr 4:148,864,048...148,867,612
Ensembl chr 4:148,864,044...148,867,612 Ensembl chr 3:148,864,044...148,867,612
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions increases phosphorylation |
EXP |
dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Pilocarpine results in increased phosphorylation of RPS6 protein]]; Resveratrol inhibits the reaction [Pilocarpine results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:23211629 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
S100b |
S100 calcium binding protein B |
increases expression |
EXP |
Pilocarpine results in increased expression of S100B protein |
CTD |
PMID:18226170 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Scn2b |
sodium voltage-gated channel beta subunit 2 |
decreases response to substance |
ISO |
SCN2B protein results in decreased susceptibility to Pilocarpine |
CTD |
PMID:12481039 |
|
NCBI chr 8:45,425,629...45,437,765
Ensembl chr 8:45,425,629...45,437,765
|
|
G |
Scn8a |
sodium voltage-gated channel alpha subunit 8 |
increases expression |
EXP |
Pilocarpine results in increased expression of SCN8A mRNA; Pilocarpine results in increased expression of SCN8A protein |
CTD |
PMID:19306853 |
|
NCBI chr 7:131,982,152...132,156,075
Ensembl chr 7:131,982,480...132,151,292
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases expression |
EXP |
dorsomorphin inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein] |
CTD |
PMID:23211629 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
increases expression |
ISO EXP |
Pilocarpine results in increased expression of SLC12A2 mRNA; Pilocarpine results in increased expression of SLC12A2 protein |
CTD |
PMID:18550034 PMID:19674083 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc12a5 |
solute carrier family 12 member 5 |
decreases expression multiple interactions increases degradation |
ISO EXP |
Pilocarpine results in decreased expression of SLC12A5 mRNA; Pilocarpine results in decreased expression of SLC12A5 protein Pilocarpine results in increased phosphorylation of and affects the localization of SLC12A5 protein Pilocarpine results in increased degradation of SLC12A5 protein |
CTD |
PMID:18094240 PMID:18550034 PMID:19674083 PMID:20600929 |
|
NCBI chr 3:153,696,517...153,735,801
Ensembl chr 3:153,696,517...153,735,765
|
|
G |
Slc17a7 |
solute carrier family 17 member 7 |
increases expression |
EXP |
Pilocarpine results in increased expression of SLC17A7 protein |
CTD |
PMID:17503488 |
|
NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of SLC1A1 mRNA; Pilocarpine results in increased expression of SLC1A1 protein |
CTD |
PMID:11906504 |
|
NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Pilocarpine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc32a1 |
solute carrier family 32 member 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of SLC32A1 mRNA; Pilocarpine results in increased expression of SLC32A1 protein |
CTD |
PMID:17503488 |
|
NCBI chr 3:147,267,373...147,271,842
Ensembl chr 3:147,267,373...147,271,844
|
|
G |
Slc5a3 |
solute carrier family 5 member 3 |
increases response to substance increases expression affects response to substance |
ISO |
SLC5A3 gene mutant form results in increased susceptibility to Pilocarpine Pilocarpine results in increased expression of SLC5A3 mRNA SLC5A3 protein affects the susceptibility to Pilocarpine |
CTD |
PMID:17602744 PMID:19754464 PMID:21219332 |
|
NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
decreases expression |
EXP ISO |
Pilocarpine results in decreased expression of SLC6A1 protein Pilocarpine results in decreased expression of SLC6A1 mRNA |
CTD |
PMID:12183020 PMID:21219332 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Slc6a11 |
solute carrier family 6 member 11 |
decreases expression |
ISO |
Pilocarpine results in decreased expression of SLC6A11 mRNA |
CTD |
PMID:21219332 |
|
NCBI chr 4:147,297,972...147,413,319
Ensembl chr 4:147,297,969...147,413,443
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
decreases expression increases expression |
ISO |
Pilocarpine results in decreased expression of SLC6A12 mRNA Pilocarpine results in increased expression of SLC6A12 mRNA |
CTD |
PMID:21219332 |
|
NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750
|
|
G |
Slc6a6 |
solute carrier family 6 member 6 |
increases expression |
ISO |
Pilocarpine results in increased expression of SLC6A6 mRNA |
CTD |
PMID:21219332 |
|
NCBI chr 4:124,195,186...124,268,880
Ensembl chr 4:124,195,218...124,268,875
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of SLCO1A4 protein |
CTD |
PMID:19570321 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slit2 |
slit guidance ligand 2 |
increases expression decreases expression |
EXP |
Pilocarpine results in increased expression of SLIT2 protein Pilocarpine results in decreased expression of SLIT2 protein |
CTD |
PMID:20153733 |
|
NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
|
|
G |
Smc3 |
structural maintenance of chromosomes 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of SMC3 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
|
|
G |
Snta1 |
syntrophin, alpha 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of SNTA1 protein |
CTD |
PMID:20886625 |
|
NCBI chr 3:142,876,285...142,906,737
Ensembl chr 3:142,876,296...142,906,709
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of SOD2 protein |
CTD |
PMID:20446108 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sparcl1 |
SPARC like 1 |
affects localization decreases expression |
EXP |
Pilocarpine affects the localization of SPARCL1 protein Pilocarpine results in decreased expression of SPARCL1 protein |
CTD |
PMID:18488994 PMID:18808451 |
|
NCBI chr14:5,632,816...5,663,866
Ensembl chr14:5,632,569...5,663,865
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
EXP |
[Lithium co-treated with Pilocarpine] results in increased activity of SRC protein |
CTD |
PMID:16600505 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Sstr1 |
somatostatin receptor 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of SSTR1 protein |
CTD |
PMID:18951627 |
|
NCBI chr 6:75,832,292...75,836,806
Ensembl chr 6:75,832,530...75,836,802
|
|
G |
Sstr2 |
somatostatin receptor 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of SSTR2 protein |
CTD |
PMID:18951627 |
|
NCBI chr10:98,664,204...98,671,370
Ensembl chr10:98,664,216...98,674,351
|
|
G |
Sstr3 |
somatostatin receptor 3 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of SSTR3 protein |
CTD |
PMID:18951627 |
|
NCBI chr 7:110,092,563...110,109,043
Ensembl chr 7:110,092,575...110,099,769
|
|
G |
Sstr4 |
somatostatin receptor 4 |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of SSTR4 protein Pilocarpine results in increased expression of SSTR4 protein |
CTD |
PMID:18951627 |
|
NCBI chr 3:135,854,826...135,856,689
Ensembl chr 3:135,854,826...135,856,689
|
|
G |
Sstr5 |
somatostatin receptor 5 |
decreases expression increases expression |
EXP |
Pilocarpine results in decreased expression of SSTR5 protein Pilocarpine results in increased expression of SSTR5 protein |
CTD |
PMID:18951627 |
|
NCBI chr10:14,506,868...14,512,946
Ensembl chr10:14,506,868...14,512,946
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases localization |
EXP |
Pilocarpine results in increased localization of STAR protein |
CTD |
PMID:20609383 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stard6 |
StAR-related lipid transfer domain containing 6 |
increases localization increases expression |
EXP |
Pilocarpine results in increased localization of STARD6 protein Pilocarpine results in increased expression of STARD6 protein |
CTD |
PMID:19434006 PMID:20609383 |
|
NCBI chr18:64,089,618...64,118,528
Ensembl chr18:64,089,471...64,107,099
|
|
G |
Syp |
synaptophysin |
increases expression |
EXP |
Pilocarpine results in increased expression of SYP protein |
CTD |
PMID:16134595 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
[Pilocarpine co-treated with Lithium] results in increased expression of TAC1 mRNA; [Pilocarpine co-treated with Lithium] results in increased expression of TAC1 protein modified form; Dizocilpine Maleate inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased expression of TAC1 protein modified form] |
CTD |
PMID:11074153 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tdg |
thymine-DNA glycosylase |
increases expression |
EXP |
Pilocarpine results in increased expression of TDG mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 7:21,077,853...21,097,617
Ensembl chr 7:21,077,853...21,097,567
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
EXP |
Pilocarpine results in increased expression of TFAM mRNA; Pilocarpine results in increased expression of TFAM protein |
CTD |
PMID:20446108 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Thrb |
thyroid hormone receptor beta |
increases expression |
EXP |
Pilocarpine results in increased expression of THRB mRNA |
CTD |
PMID:14656328 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
increases expression |
EXP |
Pilocarpine results in increased expression of TIMP2 mRNA |
CTD |
PMID:14656328 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tjp1 |
tight junction protein 1 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of TJP1 protein |
CTD |
PMID:17533168 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
ISO |
Pilocarpine results in increased expression of TLR2 mRNA |
CTD |
PMID:15193289 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
[Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of TLR4 mRNA] |
CTD |
PMID:32494933 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnc |
tenascin C |
increases expression |
EXP |
Pilocarpine results in increased expression of TNC mRNA |
CTD |
PMID:14656328 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
increases expression decreases expression multiple interactions |
ISO EXP |
Pilocarpine results in increased expression of TNF mRNA Pilocarpine results in increased expression of TNF protein Pilocarpine results in decreased expression of TNF mRNA; Pilocarpine results in decreased expression of TNF protein [Lithium Chloride co-treated with Pilocarpine] results in increased expression of TNF mRNA; [Lithium Chloride co-treated with Pilocarpine] results in increased expression of TNF protein; Pilocarpine inhibits the reaction [Phenylephrine results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Pilocarpine results in increased expression of TNF protein] |
CTD |
PMID:15193289 PMID:17872965 PMID:18455351 PMID:19055492 PMID:31018114 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
EXP |
Pilocarpine results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf13 |
TNF superfamily member 13 |
decreases expression |
EXP |
Pilocarpine results in decreased expression of TNFSF13 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr10:54,400,054...54,403,723
Ensembl chr10:54,400,065...54,403,042
|
|
G |
Tnr |
tenascin R |
increases expression |
EXP |
Pilocarpine results in increased expression of TNR protein |
CTD |
PMID:15120744 |
|
NCBI chr13:71,751,714...72,172,731
Ensembl chr13:72,091,585...72,167,641
|
|
G |
Trex1 |
three prime repair exonuclease 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of TREX1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 8:109,706,613...109,707,913
Ensembl chr 8:109,706,613...109,708,796
|
|
G |
Trh |
thyrotropin releasing hormone |
increases expression |
EXP |
Pilocarpine results in increased expression of TRH mRNA |
CTD |
PMID:10443546 PMID:15781040 |
|
NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637
|
|
G |
Trhr |
thyrotropin releasing hormone receptor |
decreases activity decreases expression |
EXP |
Pilocarpine results in decreased activity of TRHR protein Pilocarpine results in decreased expression of TRHR protein |
CTD |
PMID:10443546 |
|
NCBI chr 7:75,348,672...75,393,310
Ensembl chr 7:75,348,672...75,393,309
|
|
G |
Ube2d3 |
ubiquitin-conjugating enzyme E2D 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of UBE2D3 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 2:223,868,397...223,899,606
Ensembl chr 2:223,868,730...223,898,081
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
increases expression |
EXP |
Pilocarpine results in increased expression of UBE2I mRNA |
CTD |
PMID:17971868 |
|
NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443 Ensembl chr10:69,701,618...69,702,443
|
|
G |
Vdr |
vitamin D receptor |
increases expression |
EXP |
Pilocarpine results in increased expression of VDR mRNA |
CTD |
PMID:18534255 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
EXP |
Pilocarpine results in increased expression of VEGFA protein |
CTD |
PMID:17533168 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vgf |
VGF nerve growth factor inducible |
increases expression |
EXP |
Pilocarpine results in increased expression of VGF mRNA |
CTD |
PMID:14656328 |
|
NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
increases expression |
EXP |
Pilocarpine results in increased expression of XRCC1 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
G |
Xrcc3 |
X-ray repair cross complementing 3 |
increases expression |
EXP |
Pilocarpine results in increased expression of XRCC3 mRNA |
CTD |
PMID:17971868 |
|
NCBI chr 6:130,863,405...130,873,765
Ensembl chr 6:130,863,959...130,872,444
|
|
G |
Zfp110 |
zinc finger protein 110 |
multiple interactions |
ISO |
ZFP110 protein mutant form inhibits the reaction [Pilocarpine results in increased cleavage of CASP3 protein] |
CTD |
PMID:18815271 |
|
NCBI chr 1:73,445,303...73,461,112
Ensembl chr 1:73,445,336...73,461,086
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
Timolol binds to and results in decreased activity of ADRB1 protein; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:11436944 PMID:15060759 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Timolol binds to and results in decreased activity of ADRB2 protein |
CTD |
PMID:11436944 PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
EXP |
Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein] |
CTD |
PMID:2860926 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance |
ISO |
CYP2D6 gene SNP affects the susceptibility to Timolol |
CTD |
PMID:19284319 PMID:20925579 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK1 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11914123 PMID:18977218 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK3 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11914123 PMID:18977218 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Rgs3 |
regulator of G-protein signaling 3 |
multiple interactions |
ISO |
RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:18977218 |
|
NCBI chr 5:76,022,038...76,161,895
Ensembl chr 5:76,022,001...76,161,894
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
ISO |
RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:18977218 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
|
G |
Arhgap45 |
Rho GTPase activating protein 45 |
affects expression |
ISO |
brinzolamide affects the expression of ARHGAP45 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 7:9,674,873...9,690,286
Ensembl chr 7:9,674,897...9,690,268
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
brinzolamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
brinzolamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
affects expression |
ISO |
brinzolamide affects the expression of HLA-A mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
Carteolol binds to and results in decreased activity of ADRB1 protein |
CTD |
PMID:11436944 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
Carteolol binds to and results in decreased activity of ADRB2 protein |
CTD |
PMID:11436944 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Arrb1 |
arrestin, beta 1 |
increases expression |
ISO |
Carteolol results in increased expression of ARRB1 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
increases expression |
ISO |
Carteolol results in increased expression of ARRB2 protein |
CTD |
PMID:37120125 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression |
ISO |
Carteolol results in increased expression of and results in increased phosphorylation of ATM protein Carteolol results in increased expression of ATM mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Cat |
catalase |
affects activity |
ISO |
Carteolol affects the activity of CAT protein |
CTD |
PMID:37120125 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl27 |
C-C motif chemokine ligand 27 |
increases expression |
ISO |
Carteolol results in increased expression of CCL27 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
affects expression |
ISO |
Carteolol affects the expression of CDKN1A mRNA |
CTD |
PMID:37120125 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
Carteolol results in increased expression of CDKN2A mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Fahd1 |
fumarylacetoacetate hydrolase domain containing 1 |
affects expression |
ISO |
Carteolol affects the expression of FAHD1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr10:13,873,539...13,874,978
Ensembl chr10:13,873,527...13,875,012
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects activity |
ISO |
Carteolol affects the activity of GPX1 protein |
CTD |
PMID:37120125 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Carteolol results in increased phosphorylation of H2AX protein |
CTD |
PMID:37120125 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hk2 |
hexokinase 2 |
affects expression |
ISO |
Carteolol affects the expression of HK2 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
Carteolol results in increased expression of IL10 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Carteolol results in increased expression of IL1A mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Carteolol results in increased expression of IL6 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lmnb1 |
lamin B1 |
decreases expression |
ISO |
Carteolol results in decreased expression of LMNB1 protein |
CTD |
PMID:37120125 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
affects localization |
ISO |
Carteolol affects the localization of MAP1LC3B protein |
CTD |
PMID:37120125 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Carteolol results in increased expression of and results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:37120125 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Carteolol results in increased expression of and results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Carteolol results in decreased expression of MKI67 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
affects expression |
ISO |
Carteolol affects the expression of MTOR protein |
CTD |
PMID:37120125 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
affects expression |
ISO |
Carteolol affects the expression of NAMPT mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects expression |
ISO |
Carteolol affects the expression of NFE2L2 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
Carteolol results in increased expression of NFKB1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression |
ISO |
Carteolol results in increased expression of NOX4 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
affects expression |
ISO |
Carteolol affects the expression of PARP1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sirt1 |
sirtuin 1 |
affects expression |
ISO |
Carteolol affects the expression of SIRT1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sod1 |
superoxide dismutase 1 |
affects activity |
ISO |
Carteolol affects the activity of SOD1 protein |
CTD |
PMID:37120125 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects activity |
ISO |
Carteolol affects the activity of SOD2 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Carteolol results in increased expression of TGFB1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Carteolol results in increased expression of TNF mRNA |
CTD |
PMID:37120125 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
affects expression |
ISO |
Carteolol affects the expression of TP53 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Vitamin A results in decreased expression of ABCB1 mRNA]; Mannitol inhibits the reaction [Vitamin A results in decreased expression of ABCB1A mRNA] |
CTD |
PMID:15327746 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
decreases expression |
ISO |
Mannitol results in decreased expression of ACACB mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acly |
ATP citrate lyase |
increases expression |
ISO |
Mannitol results in increased expression of ACLY mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Adamts18 |
ADAM metallopeptidase with thrombospondin type 1 motif, 18 |
increases expression |
ISO |
Mannitol results in increased expression of ADAMTS18 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:41,686,951...41,840,035
Ensembl chr19:41,688,617...41,839,781
|
|
G |
Aida |
axin interactor, dorsalization associated |
decreases expression |
ISO |
Mannitol results in decreased expression of AIDA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr13:94,940,311...94,967,920
Ensembl chr13:94,939,741...94,967,920
|
|
G |
Aire |
autoimmune regulator |
decreases expression |
ISO |
Mannitol results in decreased expression of AIRE mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:10,636,058...10,651,060
Ensembl chr20:10,636,123...10,651,060
|
|
G |
Aqp9 |
aquaporin 9 |
increases uptake |
EXP |
AQP9 protein results in increased uptake of Mannitol |
CTD |
PMID:9733774 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
increases expression |
ISO |
Mannitol results in increased expression of ARHGAP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
|
|
G |
Arr3 |
arrestin 3 |
increases expression |
ISO |
Mannitol results in increased expression of ARR3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:65,699,881...65,712,224
Ensembl chr X:65,698,699...65,712,153
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases phosphorylation multiple interactions |
EXP |
Mannitol results in increased phosphorylation of BAD protein wortmannin inhibits the reaction [Mannitol results in increased phosphorylation of BAD protein] |
CTD |
PMID:15786717 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of BAX protein] |
CTD |
PMID:29803612 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
decreases expression |
ISO |
Mannitol results in decreased expression of BBOX1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Mannitol results in increased expression of BCL2 protein |
CTD |
PMID:15786717 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cables2 |
Cdk5 and Abl enzyme substrate 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of CABLES2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:167,347,527...167,362,274
Ensembl chr 3:167,347,461...167,362,279
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
IGF1 inhibits the reaction [Mannitol results in increased activity of CASP3 protein]; Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased activity of CASP3 protein] |
CTD |
PMID:10567913 PMID:12011046 PMID:29803612 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Mannitol results in increased activity of CASP9 protein |
CTD |
PMID:12011046 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cbx1 |
chromobox 1 |
increases expression |
ISO |
Mannitol results in increased expression of CBX1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096
|
|
G |
Ccdc127 |
coiled-coil domain containing 127 |
decreases expression |
ISO |
Mannitol results in decreased expression of CCDC127 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:28,928,420...28,935,885
Ensembl chr 1:28,928,325...28,935,893
|
|
G |
Ccn3 |
cellular communication network factor 3 |
decreases expression |
ISO |
Mannitol results in decreased expression of CCN3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ckap5 |
cytoskeleton associated protein 5 |
increases expression |
ISO |
Mannitol results in increased expression of CKAP5 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:77,491,195...77,593,300
Ensembl chr 3:77,491,276...77,593,264
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
affects response to substance |
ISO |
CLCN3 protein affects the susceptibility to Mannitol deficiency |
CTD |
PMID:22108225 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Ctnna2 |
catenin alpha 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of CTNNA2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:109,294,249...110,443,409
Ensembl chr 4:109,293,978...110,443,522
|
|
G |
Dbh |
dopamine beta-hydroxylase |
increases expression |
ISO |
Mannitol results in increased expression of DBH mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Dctn2 |
dynactin subunit 2 |
increases expression |
ISO |
Mannitol results in increased expression of DCTN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
increases expression |
ISO |
Mannitol results in increased expression of DGKA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Elf2 |
E74 like ETS transcription factor 2 |
increases expression |
ISO |
Mannitol results in increased expression of ELF2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:135,292,291...135,385,942
Ensembl chr 2:135,294,906...135,385,947
|
|
G |
Fam185a |
family with sequence similarity 185, member A |
increases expression |
ISO |
Mannitol results in increased expression of FAM185A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:13,542,022...13,662,967
Ensembl chr 4:13,608,464...13,662,967
|
|
G |
Fam222a |
family with sequence similarity 222, member A |
decreases expression |
ISO |
Mannitol results in decreased expression of FAM222A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:41,982,064...42,033,085
Ensembl chr12:41,986,780...42,033,682
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
decreases export decreases expression multiple interactions |
EXP ISO |
Mannitol results in decreased export of FGF23 protein Mannitol results in decreased expression of FGF23 mRNA Mannitol inhibits the reaction [Sodium Chloride deficiency results in increased expression of FGF23 mRNA]; Mannitol inhibits the reaction [Sodium Chloride deficiency results in increased expression of FGF23 protein] |
CTD |
PMID:37992803 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Mannitol results in increased expression of FOS mRNA |
CTD |
PMID:11557636 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gal3st2 |
galactose-3-O-sulfotransferase 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of GAL3ST2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:94,382,456...94,387,990
Ensembl chr 9:94,376,174...94,389,174
|
|
G |
Gas2l2 |
growth arrest-specific 2 like 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of GAS2L2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:68,222,475...68,229,877
Ensembl chr10:68,222,475...68,229,881
|
|
G |
Gpc6 |
glypican 6 |
increases expression |
ISO |
Mannitol results in increased expression of GPC6 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:94,030,218...95,027,883
Ensembl chr15:94,029,884...95,024,006
|
|
G |
Gpr19 |
G protein-coupled receptor 19 |
decreases expression |
ISO |
Mannitol results in decreased expression of GPR19 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:167,710,944...167,739,232
Ensembl chr 4:167,710,666...167,741,036
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Mannitol results in increased expression of HMOX1 mRNA |
CTD |
PMID:11592956 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases expression |
ISO |
Mannitol results in increased expression of HPRT1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hrh2 |
histamine receptor H 2 |
increases expression |
ISO |
Mannitol results in increased expression of HRH2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of ICAM1 protein] |
CTD |
PMID:16285992 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
IGF1 inhibits the reaction [Mannitol results in increased activity of CASP3 protein] |
CTD |
PMID:10567913 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Rotenone inhibits the reaction [Mannitol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]] |
CTD |
PMID:23867654 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Mannitol results in increased expression of JUN mRNA |
CTD |
PMID:11557636 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Khdc3 |
KH domain containing 3, subcortical maternal complex member |
increases expression |
ISO |
Mannitol results in increased expression of KHDC3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:73,842,344...73,844,248
Ensembl chr 8:73,842,344...73,844,248
|
|
G |
Krtap11-1 |
keratin associated protein 11-1 |
increases expression |
ISO |
Mannitol results in increased expression of KRTAP11-1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:28,809,940...28,810,944
Ensembl chr11:28,810,341...28,810,892
|
|
G |
Lsm6 |
LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated |
decreases expression |
ISO |
Mannitol results in decreased expression of LSM6 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:29,098,254...29,112,858
Ensembl chr13:42,114,032...42,116,484 Ensembl chr19:42,114,032...42,116,484
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K1 protein] |
CTD |
PMID:16510265 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K2 protein] |
CTD |
PMID:16510265 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Mannitol promotes the reaction [potassium chromate(VI) results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:10910949 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Mannitol promotes the reaction [potassium chromate(VI) results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:10910949 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mta2 |
metastasis associated 1 family, member 2 |
increases expression |
ISO |
Mannitol results in increased expression of MTA2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:205,838,181...205,846,903
Ensembl chr 1:205,837,964...205,846,946
|
|
G |
Myl9 |
myosin light chain 9 |
decreases phosphorylation |
EXP |
Mannitol results in decreased phosphorylation of MYL9 protein |
CTD |
PMID:17272349 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk3 |
myosin light chain kinase 3 |
increases expression |
ISO |
Mannitol results in increased expression of MYLK3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954
|
|
G |
Naalad2 |
N-acetylated alpha-linked acidic dipeptidase 2 |
increases expression |
ISO |
Mannitol results in increased expression of NAALAD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:15,406,119...15,479,714
Ensembl chr 8:15,407,043...15,479,714
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
decreases expression |
ISO |
Mannitol results in decreased expression of NDUFA13 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726 Ensembl chr 7:19,526,565...19,535,726
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
increases expression multiple interactions |
ISO EXP |
Mannitol results in increased expression of NFAT5 mRNA Mannitol results in increased expression of NFAT5 mRNA; Mannitol results in increased expression of NFAT5 protein Mannitol inhibits the reaction [Sodium Chloride deficiency results in decreased expression of NFAT5 mRNA] |
CTD |
PMID:23867654 PMID:37992803 |
|
NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675
|
|
G |
Nkg7 |
natural killer cell granule protein 7 |
increases expression |
ISO |
Mannitol results in increased expression of NKG7 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:93,844,748...93,845,975
Ensembl chr 1:93,844,902...93,845,983
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
Mannitol results in increased expression of NPPA protein |
CTD |
PMID:2177369 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nts |
neurotensin |
increases transport |
EXP |
NTS protein results in increased transport of Mannitol |
CTD |
PMID:11208724 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Pcp2 |
Purkinje cell protein 2 |
increases expression |
ISO |
Mannitol results in increased expression of PCP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:1,681,659...1,683,899
Ensembl chr12:1,681,659...1,683,899
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression decreases expression |
ISO |
Mannitol results in increased expression of PDCD4 mRNA Mannitol results in decreased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Phex |
phosphate regulating endopeptidase X-linked |
increases expression |
EXP |
Mannitol results in increased expression of PHEX mRNA |
CTD |
PMID:37992803 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Plcl2 |
phospholipase C-like 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of PLCL2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:3,292,564...3,477,009
Ensembl chr 9:3,292,695...3,477,009
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Mannitol results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:183,544,487...183,552,928
Ensembl chr 2:183,544,499...183,552,785
|
|
G |
Pou1f1 |
POU class 1 homeobox 1 |
increases expression |
ISO |
Mannitol results in increased expression of POU1F1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:3,316,818...3,334,804
Ensembl chr11:3,317,058...3,334,801
|
|
G |
Ppp1r10 |
protein phosphatase 1, regulatory subunit 10 |
decreases expression |
ISO |
Mannitol results in decreased expression of PPP1R10 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:2,822,995...2,838,125
Ensembl chr20:2,822,995...2,837,611
|
|
G |
Ppp4c |
protein phosphatase 4, catalytic subunit |
increases expression |
ISO |
Mannitol results in increased expression of PPP4C mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:181,392,899...181,399,703
Ensembl chr 1:181,392,923...181,399,659
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of PRKCB protein alternative form]; Mannitol inhibits the reaction [Glucose results in increased expression of PRKCB protein] |
CTD |
PMID:16285992 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of PRKCD protein] |
CTD |
PMID:16285992 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
increases expression |
EXP |
Mannitol results in increased expression of PTGER1 mRNA |
CTD |
PMID:12888618 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
decreases expression |
EXP |
Mannitol results in decreased expression of PTGER4 mRNA |
CTD |
PMID:12888618 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Mannitol results in decreased phosphorylation of and results in increased degradation of PTK2 protein]; Mannitol results in decreased phosphorylation of and results in increased degradation of PTK2 protein |
CTD |
PMID:12011046 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ralgdsl3 |
ral guanine nucleotide dissociation stimulator like 3 |
increases expression |
ISO |
Mannitol results in increased expression of RGL3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:20,500,846...20,520,471
Ensembl chr 8:20,500,846...20,520,471
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
Mannitol results in decreased expression of RBL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbp2 |
retinol binding protein 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of RBP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:99,079,293...99,104,489
Ensembl chr 8:99,079,104...99,104,473
|
|
G |
Samd10 |
sterile alpha motif domain containing 10 |
decreases expression |
ISO |
Mannitol results in decreased expression of SAMD10 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:168,700,280...168,704,427
Ensembl chr 3:168,700,284...168,705,248
|
|
G |
Sbsn |
suprabasin |
decreases expression |
ISO |
Mannitol results in decreased expression of SBSN mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:85,978,970...86,006,034
Ensembl chr 1:86,001,567...86,006,034
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of SELE mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of SELE protein] |
CTD |
PMID:16285992 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sgsm3 |
small G protein signaling modulator 3 |
decreases expression |
ISO |
Mannitol results in decreased expression of SGSM3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:112,514,453...112,544,109
Ensembl chr 7:112,514,630...112,544,108
|
|
G |
Slc12a1 |
solute carrier family 12 member 1 |
increases activity multiple interactions |
EXP |
Mannitol results in increased activity of SLC12A1 protein [Mannitol results in increased activity of SLC12A1 protein] which results in increased import of Water |
CTD |
PMID:12433675 |
|
NCBI chr 3:112,406,140...112,482,913
Ensembl chr 3:112,406,140...112,482,899
|
|
G |
Slc2a8 |
solute carrier family 2 member 8 |
decreases expression |
ISO |
Mannitol results in decreased expression of SLC2A8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:16,274,918...16,284,536
Ensembl chr 3:16,274,925...16,284,464
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Vitamin A results in increased phosphorylation of SRC protein] |
CTD |
PMID:16510265 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stx8 |
syntaxin 8 |
decreases expression |
ISO |
Mannitol results in decreased expression of STX8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:52,655,643...52,900,048
Ensembl chr10:52,654,990...52,894,993
|
|
G |
Timd4 |
T-cell immunoglobulin and mucin domain containing 4 |
decreases expression |
ISO |
Mannitol results in decreased expression of TIMD4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:31,185,751...31,221,843
Ensembl chr10:31,185,731...31,220,966
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]]; Mannitol inhibits the reaction [Quartz results in increased secretion of TNF protein] |
CTD |
PMID:19298665 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases expression |
ISO |
Mannitol results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] |
CTD |
PMID:29803612 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpd52 |
tumor protein D52 |
decreases expression increases expression |
ISO |
Mannitol results in decreased expression of TPD52 mRNA Mannitol results in increased expression of TPD52 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622
|
|
G |
Triml1 |
tripartite motif family-like 1 |
increases expression |
ISO |
Mannitol results in increased expression of TRIML1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:48,994,968...49,005,343
Ensembl chr16:48,997,252...49,005,417
|
|
G |
Ulbp1 |
UL16 binding protein 1 |
increases expression |
ISO |
Mannitol results in increased expression of ULBP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:1,694,255...1,716,160
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of VCAM1 protein] |
CTD |
PMID:16285992 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Wdr20 |
WD repeat domain 20 |
decreases expression |
ISO |
Mannitol results in decreased expression of WDR20 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:129,751,952...129,821,464
Ensembl chr 6:129,752,014...129,847,339
|
|
G |
Zfp13 |
zinc finger protein 13 |
decreases expression |
ISO |
Mannitol results in decreased expression of ZFP13 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:12,615,455...12,623,615
Ensembl chr10:12,615,190...12,623,615
|
|
G |
Zg16 |
zymogen granule protein 16 |
decreases expression |
ISO |
Mannitol results in decreased expression of ZG16 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:181,657,722...181,660,079
Ensembl chr 1:181,657,722...181,660,079
|
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Dichlorphenamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
Dichlorphenamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of ACHE protein |
CTD |
PMID:16978018 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Echothiophate Iodide binds to ALB protein |
CTD |
PMID:15525694 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity multiple interactions |
ISO |
Echothiophate Iodide results in decreased activity of BCHE protein Echothiophate Iodide inhibits the reaction [BCHE protein results in increased hydrolysis of Butyrylthiocholine] |
CTD |
PMID:7377577 PMID:16213467 PMID:17698511 PMID:21802514 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of NCEH1 protein |
CTD |
PMID:16978018 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions |
ISO |
Ethoxzolamide binds to and results in decreased activity of CA1 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Ethoxzolamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
Ethoxzolamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
fluprostenol inhibits the reaction [Niacin results in increased expression of FABP4 mRNA] |
CTD |
PMID:21236357 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
decreases expression |
EXP |
fluprostenol results in decreased expression of FGFR2 mRNA |
CTD |
PMID:15654655 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein] fluprostenol results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:33486071 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein] fluprostenol results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:33486071 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
fluprostenol inhibits the reaction [Niacin results in increased expression of PPARG mRNA] |
CTD |
PMID:21236357 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgfr |
prostaglandin F receptor |
multiple interactions |
ISO |
PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:240,733,375...240,765,650
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
latanoprost results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
affects expression |
ISO |
Levobunolol affects the expression of HLA-DMB mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in increased expression of BCL2 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in increased expression of BCL2 protein] |
CTD |
PMID:16799065 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Metipranolol inhibits the reaction [Zinc results in increased cleavage of CASP3 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP3 protein] |
CTD |
PMID:16799065 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Grk1 |
G protein-coupled receptor kinase 1 |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in decreased expression of GRK1 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in decreased expression of GRK1 protein] |
CTD |
PMID:16799065 |
|
NCBI chr16:76,122,501...76,135,792
Ensembl chr16:76,123,842...76,135,792
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in decreased expression of PARP1 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in decreased expression of PARP1 protein] |
CTD |
PMID:16799065 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
increases expression affects binding increases activity multiple interactions |
ISO EXP |
Pindolol results in increased expression of ADRB1 protein Pindolol binds to ADRB1 protein Pindolol results in increased activity of ADRB1 protein [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; CGP 20712A affects the reaction [Pindolol results in increased activity of ADRB1 protein]; Pindolol binds to and results in decreased activity of ADRB1 protein; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [cyanopindolol binds to ADRB1 protein] Pindolol binds to and results in decreased activity of ADRB1 protein; Pindolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Pindolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] |
CTD |
PMID:2175014 PMID:2462161 PMID:2888869 PMID:12761341 PMID:14730417 PMID:15060759 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases expression affects binding multiple interactions |
ISO EXP |
Pindolol results in decreased expression of ADRB2 protein Pindolol binds to ADRB2 protein Pindolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Pindolol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein] [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Pindolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Pindolol binds to and results in decreased activity of ADRB2 protein; Pindolol inhibits the reaction [cyanopindolol binds to ADRB2 protein] |
CTD |
PMID:2175014 PMID:2462161 PMID:14730417 PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
EXP ISO |
Pindolol binds to and results in increased activity of ADRB3 protein [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Pindolol binds to and results in increased activity of ADRB3 protein; Pindolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:1682311 PMID:7815362 PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
Pindolol inhibits the reaction [REN protein results in increased cleavage of AGT protein] |
CTD |
PMID:7104148 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
Pindolol binds to and affects the activity of HTR1A protein; Pindolol binds to and results in decreased activity of HTR1A protein |
CTD |
PMID:2207497 PMID:9809859 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
affects binding |
EXP |
Pindolol binds to HTR1B protein |
CTD |
PMID:11888550 |
|
NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Pindolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:17925438 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Pindolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO EXP |
Pindolol inhibits the reaction [Buspirone results in increased secretion of PRL protein] |
CTD |
PMID:18194152 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ren |
renin |
multiple interactions decreases expression decreases activity |
ISO |
Pindolol inhibits the reaction [REN protein results in increased cleavage of AGT protein] Pindolol results in decreased expression of REN protein Pindolol results in decreased activity of REN protein |
CTD |
PMID:791319 PMID:973972 PMID:7104148 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|